Skip to main content
Back to feed
HealthSingle-sourceLowDeveloping
2.1

EMA recommends marketing authorization for Minoryx's Nezglyal

The European Medicines Agency has issued a positive opinion for the commercialization of Nezglyal to treat cerebral adrenoleukodystrophy. This regulatory milestone marks a significant advancement for the rare disease therapy, pending final European Commission approval.

Expansión3 days agoES, EUCredibility 26%View source

Score Breakdown

Mosaic Score2.1
Confidence0.9
Significance0.1
Source credibility0.3

Intelligence Tags

#pharmaceuticals#ema#rare-diseases#biotech#regulatory-approval

Entities

organization
Source

Related signals

8 found